Agios Pharmaceuticals vs 4d Molecular Therapeutics
4d Molecular Therapeutics is the larger business, with $85.2m of revenue in fiscal 2025 against $54.0m for Agios Pharmaceuticals (1.6 times as much). 4d Molecular Therapeutics grew faster (230194.6% against 48.0%). 4d Molecular Therapeutics kept more of each dollar of sales as profit: a net margin of -164.4% against -764.0%. Agios Pharmaceuticals carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Agios PharmaceuticalsAGIO, 2025 | 4d Molecular TherapeuticsFDMT, 2025 |
|---|---|---|
| Revenue | $54.0m | $85.2m |
| Revenue growth | 48.0% | 230194.6% |
| Net income | −$413m | −$140m |
| Operating margin | -873.9% | -187.2% |
| Net margin | -764.0% | -164.4% |
| Return on equity | -30.2% | -27.6% |
| Free cash flow | −$377m | −$110m |
| Cash | $89.1m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 539 | 196 |
| Market value | $1.87bn | $656m |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 40 sales | 0 buys, 25 sales |